665 related articles for article (PubMed ID: 1909701)
1. Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion.
Sklar CA; Rothenberg S; Blumberg D; Oberfield SE; Levine LS; David R
J Clin Endocrinol Metab; 1991 Oct; 73(4):734-8. PubMed ID: 1909701
[TBL] [Abstract][Full Text] [Related]
2. Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty.
Mansfield MJ; Rudlin CR; Crigler JF; Karol KA; Crawford JD; Boepple PA; Crowley WF
J Clin Endocrinol Metab; 1988 Jan; 66(1):3-9. PubMed ID: 2961786
[TBL] [Abstract][Full Text] [Related]
3. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
[TBL] [Abstract][Full Text] [Related]
4. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
Garibaldi LR; Aceto T; Weber C; Pang S
J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
[TBL] [Abstract][Full Text] [Related]
5. Suppression of sex steroids by a gonadotrophin-releasing hormone agonist increases serum growth hormone-binding protein activity in girls with central idiopathic precocious puberty.
Kobayashi Y; Murata A; Yasuda T; Minagawa M; Wataki K; Ohnishi H; Niimi H
Clin Endocrinol (Oxf); 1994 Mar; 40(3):351-5. PubMed ID: 8187298
[TBL] [Abstract][Full Text] [Related]
6. The effect of long-acting analog of luteinizing hormone-releasing hormone on growth hormone secretory dynamics in children with precocious puberty.
DiMartino-Nardi J; Wu R; Fishman K; Saenger P
J Clin Endocrinol Metab; 1991 Oct; 73(4):902-6. PubMed ID: 1909708
[TBL] [Abstract][Full Text] [Related]
7. The effect of luteinizing hormone-releasing hormone analog for central precocious puberty on growth hormone (GH) and GH-binding protein.
DiMartino-Nardi J; Wu R; Varner R; Wong WL; Saenger P
J Clin Endocrinol Metab; 1994 Mar; 78(3):664-8. PubMed ID: 8126139
[TBL] [Abstract][Full Text] [Related]
8. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
[TBL] [Abstract][Full Text] [Related]
9. The pubertal growth spurt in eight patients with true precocious puberty and growth hormone deficiency: evidence for a direct role of sex steroids.
Attie KM; Ramirez NR; Conte FA; Kaplan SL; Grumbach MM
J Clin Endocrinol Metab; 1990 Oct; 71(4):975-83. PubMed ID: 2401720
[TBL] [Abstract][Full Text] [Related]
10. Age-related alterations in pituitary and testicular functions in long-lived growth hormone receptor gene-disrupted mice.
Chandrashekar V; Dawson CR; Martin ER; Rocha JS; Bartke A; Kopchick JJ
Endocrinology; 2007 Dec; 148(12):6019-25. PubMed ID: 17872367
[TBL] [Abstract][Full Text] [Related]
11. Somatomedin-C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist.
Harris DA; Van Vliet G; Egli CA; Grumbach MM; Kaplan SL; Styne DM; Vainsel M
J Clin Endocrinol Metab; 1985 Jul; 61(1):152-9. PubMed ID: 3889035
[TBL] [Abstract][Full Text] [Related]
12. Low growth hormone levels are related to increased body mass index and do not reflect impaired growth in luteinizing hormone-releasing hormone agonist-treated children with precocious puberty.
Kamp GA; Manasco PK; Barnes KM; Jones J; Rose SR; Hill SC; Cutler GB
J Clin Endocrinol Metab; 1991 Feb; 72(2):301-7. PubMed ID: 1991801
[TBL] [Abstract][Full Text] [Related]
13. Irreversible increase of serum IGF-1 and IGFBP-3 levels in GnRH-dependent precocious puberty of different etiologies: implications for the onset of puberty.
Belgorosky A; Rivarola MA
Horm Res; 1998; 49(5):226-32. PubMed ID: 9568807
[TBL] [Abstract][Full Text] [Related]
14. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
Neely EK; Hintz RL; Parker B; Bachrach LK; Cohen P; Olney R; Wilson DM
J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
[TBL] [Abstract][Full Text] [Related]
15. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM
J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
[TBL] [Abstract][Full Text] [Related]
16. GnRH agonist stimulation of the pituitary-gonadal axis in children: age and sex differences in circulating inhibin-B and activin-A.
Elsholz DD; Padmanabhan V; Rosenfield RL; Olton PR; Phillips DJ; Foster CM
Hum Reprod; 2004 Dec; 19(12):2748-58. PubMed ID: 15513981
[TBL] [Abstract][Full Text] [Related]
17. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
[TBL] [Abstract][Full Text] [Related]
18. Serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 levels in children with precocious puberty treated with gonadotropin-releasing hormone analog without or in combination with cyproterone acetate.
Verrotti A; Ferrari M; Sabatino G; Morgese G; Chiarelli F
Gynecol Endocrinol; 1997 Aug; 11(4):243-50. PubMed ID: 9272420
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation.
Mansfield MJ; Beardsworth DE; Loughlin JS; Crawford JD; Bode HH; Rivier J; Vale W; Kushner DC; Crigler JF; Crowley WF
N Engl J Med; 1983 Nov; 309(21):1286-90. PubMed ID: 6415479
[TBL] [Abstract][Full Text] [Related]
20. Overnight levels of luteinizing hormone, follicle-stimulating hormone and growth hormone before and during gonadotropin-releasing hormone analogue treatment in short boys born small for gestational age.
van der Kaay DC; de Jong FH; Rose SR; Odink RJ; Bakker-van Waarde WM; Sulkers EJ; Hokken-Koelega AC
Horm Res; 2009; 71(5):260-7. PubMed ID: 19339790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
